JP2005530490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530490A5 JP2005530490A5 JP2003582268A JP2003582268A JP2005530490A5 JP 2005530490 A5 JP2005530490 A5 JP 2005530490A5 JP 2003582268 A JP2003582268 A JP 2003582268A JP 2003582268 A JP2003582268 A JP 2003582268A JP 2005530490 A5 JP2005530490 A5 JP 2005530490A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- amino acid
- antibody
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000002773 nucleotide Substances 0.000 claims 20
- 125000003729 nucleotide group Chemical group 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 102000000743 Interleukin-5 Human genes 0.000 claims 7
- 108010002616 Interleukin-5 Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 102000010786 Interleukin-5 Receptors Human genes 0.000 claims 4
- 108010038484 Interleukin-5 Receptors Proteins 0.000 claims 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 4
- 230000002452 interceptive effect Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010014950 Eosinophilia Diseases 0.000 claims 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003979 eosinophil Anatomy 0.000 claims 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 2
- 230000008595 infiltration Effects 0.000 claims 2
- 238000001764 infiltration Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000037874 Asthma exacerbation Diseases 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000006968 Helminthiasis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000243981 Onchocerca Species 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039094 Rhinitis perennial Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 230000009471 action Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000010085 airway hyperresponsiveness Effects 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 230000001667 episodic effect Effects 0.000 claims 1
- 230000008378 epithelial damage Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 210000003716 mesoderm Anatomy 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 208000016366 nasal cavity polyp Diseases 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36904402P | 2002-03-29 | 2002-03-29 | |
| PCT/US2003/009260 WO2003085089A2 (en) | 2002-03-29 | 2003-03-27 | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009243925A Division JP2010011874A (ja) | 2002-03-29 | 2009-10-22 | インターロイキン−５に対するヒトモノクローナル抗体および方法およびこれを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530490A JP2005530490A (ja) | 2005-10-13 |
| JP2005530490A5 true JP2005530490A5 (enExample) | 2006-04-20 |
Family
ID=28791919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003582268A Ceased JP2005530490A (ja) | 2002-03-29 | 2003-03-27 | インターロイキン−５に対するヒトモノクローナル抗体および方法およびこれを含む組成物 |
| JP2009243925A Pending JP2010011874A (ja) | 2002-03-29 | 2009-10-22 | インターロイキン−５に対するヒトモノクローナル抗体および方法およびこれを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009243925A Pending JP2010011874A (ja) | 2002-03-29 | 2009-10-22 | インターロイキン−５に対するヒトモノクローナル抗体および方法およびこれを含む組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7141653B2 (enExample) |
| EP (1) | EP1527100B1 (enExample) |
| JP (2) | JP2005530490A (enExample) |
| CN (1) | CN1326879C (enExample) |
| AT (1) | ATE435239T1 (enExample) |
| AU (1) | AU2003220525A1 (enExample) |
| CA (1) | CA2479927C (enExample) |
| CY (1) | CY1109423T1 (enExample) |
| DE (1) | DE60328195D1 (enExample) |
| DK (1) | DK1527100T3 (enExample) |
| ES (1) | ES2327830T3 (enExample) |
| MX (1) | MXPA04009418A (enExample) |
| PT (1) | PT1527100E (enExample) |
| SI (1) | SI1527100T1 (enExample) |
| WO (1) | WO2003085089A2 (enExample) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| MXPA04009418A (es) * | 2002-03-29 | 2005-06-08 | Schering Corp | Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos. |
| DE60332483D1 (de) | 2002-11-15 | 2010-06-17 | Novartis Vaccines & Diagnostic | Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust |
| WO2005047324A2 (en) | 2003-11-10 | 2005-05-26 | Schering Corp | Interleukin-10 antibodies |
| EP3476861A1 (en) | 2004-01-07 | 2019-05-01 | Novartis Vaccines and Diagnostics, Inc. | M-csf-specific monoclonal antibody and uses thereof |
| PL2070530T3 (pl) * | 2004-05-14 | 2016-06-30 | Merck Sharp & Dohme | Leczenie chorób związanych ze stosowaniem antybiotyków |
| JP4954709B2 (ja) * | 2004-10-28 | 2012-06-20 | 協和発酵キリン株式会社 | 子宮内膜症治療剤 |
| US8030003B2 (en) * | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| EP1913027B1 (en) * | 2005-07-28 | 2015-03-04 | Novartis AG | M-csf specific monoclonal antibody and uses thereof |
| WO2007016240A2 (en) * | 2005-07-28 | 2007-02-08 | Novartis Ag | Use of antibody to m-csf |
| US9062126B2 (en) | 2005-09-16 | 2015-06-23 | Raptor Pharmaceuticals Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof |
| KR20080068062A (ko) | 2005-11-14 | 2008-07-22 | 리나트 뉴로사이언스 코퍼레이션 | 칼시토닌 유전자-관련 펩티드에 대해 지시되는 길항제 항체및 그의 사용 방법 |
| JP2009519983A (ja) * | 2005-12-20 | 2009-05-21 | アラーナ・テラピューティクス・リミテッド | 部分的な新世界ザル結合領域を有するキメラ抗体 |
| EA017417B1 (ru) | 2006-02-01 | 2012-12-28 | Сефалон Астралия Пти Лтд. | КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ |
| WO2007111661A2 (en) | 2006-03-20 | 2007-10-04 | Xoma Technology Ltd. | Human antibodies specific for gastrin materials and methods |
| WO2008011571A1 (en) * | 2006-07-21 | 2008-01-24 | Amgen Inc. | Polypeptides with reduced susceptibility to oxidation and methods of making |
| JP2008027370A (ja) | 2006-07-25 | 2008-02-07 | Fujitsu Ltd | 電子機器 |
| JP5148079B2 (ja) | 2006-07-25 | 2013-02-20 | 富士通株式会社 | 液冷ユニット用熱交換器および液冷ユニット並びに電子機器 |
| JP4842040B2 (ja) | 2006-07-25 | 2011-12-21 | 富士通株式会社 | 電子機器 |
| JP4781929B2 (ja) | 2006-07-25 | 2011-09-28 | 富士通株式会社 | 電子機器 |
| US8586716B2 (en) | 2006-08-04 | 2013-11-19 | Novartis Ag | EPHB3-specific antibody and uses thereof |
| EP3018144A1 (en) | 2006-08-18 | 2016-05-11 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
| WO2008036899A2 (en) * | 2006-09-22 | 2008-03-27 | Amgen Inc. | Methods for removing viral contaminants during protein purification |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CA2663536A1 (en) * | 2006-10-24 | 2008-05-02 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
| US7846434B2 (en) * | 2006-10-24 | 2010-12-07 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
| KR20140119831A (ko) | 2006-12-07 | 2014-10-10 | 노파르티스 아게 | Ｅｐｈｂ３에 대한 길항제 항체 |
| WO2008077145A2 (en) | 2006-12-20 | 2008-06-26 | Xoma Technology Ltd. | Treatment of il-1-beta related diseases |
| PE20090722A1 (es) | 2007-02-02 | 2009-07-13 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| EP2508613A3 (en) | 2007-04-03 | 2012-11-28 | Oxyrane UK Limited | Glycosylation of molecules |
| PT2152290E (pt) * | 2007-04-30 | 2014-09-03 | Glaxosmithkline Llc | Métodos para administrar anticorpos anti-il-5 |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| TWI595005B (zh) * | 2007-08-21 | 2017-08-11 | 安健股份有限公司 | 人類ｃ－ｆｍｓ抗原結合蛋白質 |
| CA2701032C (en) | 2007-09-27 | 2021-01-26 | Amgen Inc. | Pharmaceutical formulations |
| EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
| JP5536666B2 (ja) | 2007-12-20 | 2014-07-02 | ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー | 痛風の治療のための方法 |
| CA2711826C (en) | 2008-01-25 | 2018-02-27 | Amgen Inc. | Ferroportin antibodies and methods of use |
| ES2689322T3 (es) | 2008-03-04 | 2018-11-13 | Teva Pharmaceuticals International Gmbh | Métodos para tratar el dolor crónico |
| AU2009228163B2 (en) | 2008-03-28 | 2012-08-30 | Glaxosmithkline Llc | Methods of treatment |
| EP2816059A1 (en) | 2008-05-01 | 2014-12-24 | Amgen, Inc | Anti-hepcidin antibodies and methods of use |
| US8128932B2 (en) * | 2009-08-17 | 2012-03-06 | Shanghai Aosaiersi Biotech Co., Ltd. | Anti-VEGFR monoclonal antibody, method of making and uses thereof |
| RU2535074C2 (ru) | 2009-08-28 | 2014-12-10 | Лэйбрис Байолоджикс, Инк. | Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина |
| EP3187877A1 (en) | 2009-09-25 | 2017-07-05 | XOMA Technology Ltd. | Screening methods |
| US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| JP5990102B2 (ja) | 2009-09-29 | 2016-09-07 | ユニフェルシテイト ヘント | ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解 |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| BR112012011980A2 (pt) | 2009-11-19 | 2021-09-08 | Oxyrane Uk Limited | Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas |
| WO2011089527A1 (en) | 2010-01-21 | 2011-07-28 | Oxyrane Uk Limited | Methods and compositions for displaying a poypeptide on a yeast cell surface |
| SG189110A1 (en) | 2010-09-29 | 2013-05-31 | Oxyrane Uk Ltd | De-mannosylation of phosphorylated n-glycans |
| CA2812870C (en) | 2010-09-29 | 2020-06-09 | Oxyrane Uk Limited | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
| CN103429261A (zh) * | 2010-12-22 | 2013-12-04 | 塞法隆澳大利亚股份有限公司 | 半寿期改进的修饰抗体 |
| US9745373B2 (en) | 2011-05-20 | 2017-08-29 | Alderbio Holdings Llc | Anti-CGRP compositions and use thereof |
| SG194973A1 (en) | 2011-05-20 | 2013-12-30 | Alderbio Holdings Llc | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| AU2012258976B8 (en) | 2011-05-20 | 2017-07-20 | H. Lundbeck A/S | Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| AU2012261933B2 (en) | 2011-06-03 | 2017-06-15 | Xoma Technology Ltd. | Antibodies specific for TGF-beta |
| AU2012272559C1 (en) | 2011-06-23 | 2017-04-20 | Children's Hospital Medical Center | Molecular diagnostic panel of eosinophilic gastrointestinal disorders |
| EP2794657B1 (en) | 2011-12-19 | 2017-10-11 | Xoma (Us) Llc | Methods for treating acne |
| ES2886123T3 (es) | 2012-01-31 | 2021-12-16 | Regeneron Pharma | Anticuerpos anti-asic1 y usos de los mismos |
| CN104379162B (zh) | 2012-03-15 | 2017-03-15 | 奥克西雷恩英国有限公司 | 用于治疗蓬佩氏病的方法和材料 |
| HUE064945T2 (hu) | 2012-08-21 | 2024-04-28 | Sanofi Biotechnology | Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával |
| US20190178879A1 (en) * | 2012-08-23 | 2019-06-13 | Stemcell Technologies Canada Inc. | Compositions and methods for rapid and reversible biomolecular labeling |
| SG11201502816YA (en) | 2012-10-12 | 2015-05-28 | Agency Science Tech & Res | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015035215A1 (en) | 2013-09-05 | 2015-03-12 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| RU2704999C2 (ru) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Способ лечения кожной инфекции путем введения антагониста il-4r |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| AU2015230933B2 (en) | 2014-03-21 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| EP3143404B1 (en) | 2014-05-16 | 2018-08-29 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| EP3218412A1 (en) | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| US11270782B2 (en) | 2014-11-19 | 2022-03-08 | Koninklijke Philips N.V. | Diagnostic method employing HNL |
| WO2016141111A1 (en) | 2015-03-03 | 2016-09-09 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
| CN108251431B (zh) * | 2015-03-05 | 2020-12-08 | 北京百特美博生物科技有限公司 | 双载体系统及其用途 |
| JP6901400B2 (ja) | 2015-04-03 | 2021-07-14 | ゾーマ テクノロジー リミテッド | ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法 |
| WO2017024285A2 (en) | 2015-08-06 | 2017-02-09 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
| EP3402572B1 (en) | 2016-01-13 | 2022-03-16 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammatory conditions |
| CN118530358A (zh) | 2016-08-01 | 2024-08-23 | 佐马美国有限公司 | 甲状旁腺激素受体1（pth1r）抗体和其用途 |
| US20190218284A1 (en) * | 2016-09-01 | 2019-07-18 | The Regents Of The University Of Colorado A Body Corporate | Methods of treating eosinophilic gastrointestinal diseases |
| EP4442323A3 (en) | 2016-09-01 | 2025-01-01 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| KR20220031944A (ko) | 2016-09-23 | 2022-03-14 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
| BR112019005944A2 (pt) | 2016-09-28 | 2019-06-11 | Musc Foudation For Res Development | anticorpos que se ligam à interleucina 2 e usos dos mesmos |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| KR102651290B1 (ko) | 2016-12-23 | 2024-03-25 | 세파론 엘엘씨 | 항-il-5 항체 |
| CN110418846A (zh) | 2017-03-14 | 2019-11-05 | 美国安进公司 | 细胞培养物中产生的抗体的总去岩藻糖基化糖型的控制 |
| US20200332344A1 (en) * | 2017-05-12 | 2020-10-22 | The Regents Of The University Of California | Treating and detecting dysbiosis |
| EP3634467A4 (en) | 2017-06-06 | 2021-07-28 | GlaxoSmithKline LLC | BIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR PEDIATRIC PATIENTS |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| MA46269B1 (fr) | 2017-08-18 | 2024-05-31 | Regeneron Pharma | Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r |
| KR102709785B1 (ko) * | 2017-09-29 | 2024-09-24 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Ｉｌ－５ 항체, 이의 항원 결합 단편 및 이의 의학적 적용 |
| RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
| HUE064655T2 (hu) | 2017-10-30 | 2024-04-28 | Sanofi Biotechnology | IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban |
| CN109942706A (zh) * | 2017-12-21 | 2019-06-28 | 三生国健药业（上海）股份有限公司 | 结合人il-5的单克隆抗体、其制备方法和用途 |
| EP3732194A1 (en) * | 2017-12-29 | 2020-11-04 | Cornell University | Gene therapy for eosinophilic disorders |
| US11859250B1 (en) | 2018-02-23 | 2024-01-02 | Children's Hospital Medical Center | Methods for treating eosinophilic esophagitis |
| SG11202009216YA (en) | 2018-03-26 | 2020-10-29 | Amgen Inc | Total afucosylated glycoforms of antibodies produced in cell culture |
| US12360103B2 (en) | 2018-04-20 | 2025-07-15 | Children's Hospital Medical Center | Blood biomarker for eosinophilic gastrointestinal disorders |
| CN112153982A (zh) | 2018-05-13 | 2020-12-29 | 瑞泽恩制药公司 | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 |
| US20220010008A1 (en) * | 2018-12-12 | 2022-01-13 | Shanghai Pharmaexplorer Co., Ltd. | Anti-human interleukin 5(il-5) monoclonal antibody and use thereof |
| AU2019395266A1 (en) * | 2018-12-14 | 2021-06-17 | Proviva Therapeutics (Hong Kong) Limited | IL-15 compositions and methods of use thereof |
| AU2020206241A1 (en) | 2019-01-08 | 2021-08-26 | H. Lundbeck A/S | Acute treatment and rapid treatment of headache using anti-CGRP antibodies |
| US12297501B2 (en) | 2019-02-25 | 2025-05-13 | Children's Hospital Medical Center | Methods for diagnosing and treating eosinophilic gastritis |
| MX2021011141A (es) | 2019-03-21 | 2022-01-19 | Regeneron Pharma | Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia. |
| MX2022000649A (es) | 2019-07-16 | 2022-06-08 | Sanofi Biotechnology | Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r. |
| EP4010001A1 (en) | 2019-08-05 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
| AU2020326713A1 (en) | 2019-08-05 | 2022-02-17 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| KR20220069982A (ko) | 2019-09-26 | 2022-05-27 | 암젠 인크 | 항체 조성물의 생산 방법 |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| CN114075282B (zh) * | 2020-08-20 | 2024-01-02 | 南京融捷康生物科技有限公司 | Il-5的结合分子及其制备方法和应用 |
| AU2021360897A1 (en) | 2020-10-15 | 2023-05-25 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| TW202317614A (zh) | 2021-06-07 | 2023-05-01 | 美商安進公司 | 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平 |
| JP2024537100A (ja) | 2021-10-05 | 2024-10-10 | アムジエン・インコーポレーテツド | Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量 |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2024220916A1 (en) | 2023-04-20 | 2024-10-24 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025038600A1 (en) | 2023-08-14 | 2025-02-20 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0267779A3 (en) | 1986-11-10 | 1990-01-17 | Schering Biotech Corporation | Human pleiotropic immune factor and muteins thereof |
| GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5096704A (en) * | 1988-11-03 | 1992-03-17 | Schering Corporation | Method of treating eosinophilia |
| KR960002183B1 (ko) * | 1988-11-03 | 1996-02-13 | 쉐링 코포레이션 | 호산구증다증 억제또는 경감을 위한 약제학적 조성물 |
| US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JPH06506105A (ja) * | 1990-08-29 | 1994-07-14 | ファーミング ビーブイ | 哺乳動物細胞における相同性組換え |
| US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| WO1993004169A1 (en) * | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| AR248044A1 (es) | 1992-02-06 | 1995-05-31 | Schering Corp | Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped. |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5625125A (en) * | 1994-08-09 | 1997-04-29 | Dnx Biotherapeutics | Phospholipase A2 expressing transgenic animals |
| US5643763A (en) * | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| EP0800536B1 (en) * | 1994-12-23 | 2006-11-29 | Smithkline Beecham Corporation | Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders |
| US5683892A (en) * | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| US6130364A (en) * | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| JPH11503914A (ja) * | 1995-04-21 | 1999-04-06 | セル ジェネシス，インコーポレイテッド | 大ゲノムｄｎａ欠失の生成 |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5714352A (en) * | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5994619A (en) * | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP2002505097A (ja) | 1998-03-03 | 2002-02-19 | アブジェニックス インク． | 治療薬としてのｃｄ１４７結合分子 |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| WO2000037504A2 (en) | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| MXPA04009418A (es) * | 2002-03-29 | 2005-06-08 | Schering Corp | Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos. |
-
2003
- 2003-03-27 MX MXPA04009418A patent/MXPA04009418A/es active IP Right Grant
- 2003-03-27 AT AT03716836T patent/ATE435239T1/de active
- 2003-03-27 CA CA2479927A patent/CA2479927C/en not_active Expired - Fee Related
- 2003-03-27 CN CNB038123975A patent/CN1326879C/zh not_active Expired - Lifetime
- 2003-03-27 WO PCT/US2003/009260 patent/WO2003085089A2/en not_active Ceased
- 2003-03-27 US US10/401,344 patent/US7141653B2/en not_active Expired - Lifetime
- 2003-03-27 DK DK03716836T patent/DK1527100T3/da active
- 2003-03-27 SI SI200331661T patent/SI1527100T1/sl unknown
- 2003-03-27 ES ES03716836T patent/ES2327830T3/es not_active Expired - Lifetime
- 2003-03-27 JP JP2003582268A patent/JP2005530490A/ja not_active Ceased
- 2003-03-27 EP EP03716836A patent/EP1527100B1/en not_active Expired - Lifetime
- 2003-03-27 PT PT03716836T patent/PT1527100E/pt unknown
- 2003-03-27 AU AU2003220525A patent/AU2003220525A1/en not_active Abandoned
- 2003-03-27 DE DE60328195T patent/DE60328195D1/de not_active Expired - Lifetime
-
2006
- 2006-10-04 US US11/542,943 patent/US7422742B2/en not_active Expired - Lifetime
-
2009
- 2009-09-23 CY CY20091100989T patent/CY1109423T1/el unknown
- 2009-10-22 JP JP2009243925A patent/JP2010011874A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005530490A5 (enExample) | ||
| JP5745854B2 (ja) | Ｔｌ１ａに対するヒト化抗体 | |
| JP2025032085A (ja) | 線維芽増殖因子受容体２に対するモノクローナル抗体 | |
| RU2427589C2 (ru) | Антитела против интерлейкина-13 человека и их применение | |
| CN104151428B (zh) | Il‑17ra‑il‑17rb拮抗物及其用途 | |
| CN113366016B (zh) | 抗人白细胞介素5(il-5)单克隆抗体及其应用 | |
| JP2009525764A5 (enExample) | ||
| EP3000827B1 (en) | Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof | |
| TW200819466A (en) | Anti-activin a antibodies and uses thereof | |
| PL207642B1 (pl) | Przeciwciało wiążące IL-1ß, konstrukt DNA, wektor ekspresyjny, kompozycja farmaceutyczna, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała | |
| CA2728909A1 (en) | Prostaglandin e2 binding proteins and uses thereof | |
| HU229523B1 (en) | Anti-tnf antibodies, compositions, methods and uses | |
| JP2008527989A5 (enExample) | ||
| CN111615519B (zh) | 结合人il-5的单克隆抗体、其制备方法和用途 | |
| RU2009120202A (ru) | Способы и композиции для лечения и мониторинга лечения связанных с il-13 расстройств | |
| JP2019505527A5 (enExample) | ||
| NZ739871A (en) | Tissue factor pathway inhibitor antibodies and uses thereof | |
| JP2017093435A (ja) | Ｉｌ−２１抗体 | |
| KR20060023968A (ko) | 중증 급성 호흡기 증후군(ｓａｒｓ)의 치료를 위한 조성물및 방법 | |
| JP2023526224A (ja) | がんを治療するための、がん治療薬との組合せでの多量体抗ｄｒ５結合分子の使用 | |
| TWI897870B (zh) | ETA抗體與TGF-β Trap的融合蛋白質，以及其藥物組合物和應用 | |
| KR20220063221A (ko) | Gipr 항체 및 이와 glp-1의 융합 단백질, 및 그의 약학 조성물 및 적용 | |
| JP2010500291A5 (enExample) | ||
| JP2014526902A (ja) | イヌ化腫瘍壊死因子抗体及びその使用方法 | |
| JP2009519720A5 (enExample) |